Related references
Note: Only part of the references are listed.IL-8 correlates with reduced baseline femoral neck bone mineral density in adults with cystic fibrosis: a single center retrospective study
Grace Y. Lam et al.
SCIENTIFIC REPORTS (2021)
Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus
R. Ali et al.
LUPUS (2019)
Cystic fibrosis bone disease treatment: Current knowledge and future directions
Melissa S. Putman et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Overexpression of RANKL in osteoblasts: a possible mechanism of susceptibility to bone disease in cystic fibrosis
Martial Delion et al.
JOURNAL OF PATHOLOGY (2016)
Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?
Frederic Velard et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Cystic Fibrosis and Bone Disease: Defective Osteoblast Maturation with the F508del Mutation in Cystic Fibrosis Transmembrane Conductance Regulator
Frederic Velard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis
J. Ambroszkiewicz et al.
ADVANCES IN MEDICAL SCIENCES (2013)
Osteoblast CFTR Inactivation Reduces Differentiation and Osteoprotegerin Expression in a Mouse Model of Cystic Fibrosis-Related Bone Disease
Michael S. Stalvey et al.
PLOS ONE (2013)
Antiresorptive therapies for osteoporosis: a clinical overview
Jian Sheng Chen et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
Lilian H. D. van Tuyl et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
The Prevalence of Osteoporosis, Osteopenia, and Fractures Among Adults with Cystic Fibrosis: A Systematic Literature Review with Meta-Analysis
J. Paccou et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E-2 in human bone
Louis Le Heron et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis
Elizabeth F. Shead et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Brendan F. Boyce et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin:: Clinical implications
Damaris Vega et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone
Elizabeth F. Shead et al.
THORAX (2007)
Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils
Patrice E. Poubelle et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss
AR Moschen et al.
GUT (2005)
Consensus statement: Guide to bone health and disease in cystic fibrosis
RM Aris et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin
AJ Ashcroft et al.
IMMUNITY (2003)
The TNF and TNF receptor superfamilies: Integrating mammalian biology
RM Locksley et al.
CELL (2001)
Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors
SP Conway et al.
THORAX (2000)
Bone density, body composition, and inflammatory status in cystic fibrosis
AA Ionescu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Share Paper
